Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092726 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT03092726 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 183 participants.
The verdict
NCT03092726, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability. This study also assessed the treatment differences in physical function as well the improvements in overall subject status (e.g., fibromyalgia symptoms, global functioning) of ASP8062 relative to placebo.
Interventions
- DRUG Placebo
- DRUG ASP8062
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2018-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03092726
The ClinicalTrials.gov registry entry for NCT03092726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03092726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03092726 about?
NCT03092726 is a clinical study titled "A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia". The purpose of this study was to assess analgesic efficacy of ASP8062 relative to placebo as well as the safety and tolerability. This study also assessed the treatment differences in physical function as well the improvements in overall subject status (e.g., fibromyalgia symptoms, global functionin...
What is the current status of trial NCT03092726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2017-05-08. Estimated completion is 2018-03-06.
What interventions are being tested in trial NCT03092726?
The interventions under investigation include: Placebo (DRUG), ASP8062 (DRUG).
Who is sponsoring clinical trial NCT03092726?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.